board members |
The Pathology Technology Australia volunteer Board of Directors is made up of recognised leaders across many areas of expertise. They represent the broad diversity of our membership and contribute significant amounts of time, talent, and energy to further the mission of our organisation.
Our Board of Directors has overall responsibility for Pathology Technology Australia's corporate governance. This includes establishing, reviewing and approving the strategic plan, policies, processes, procedures and practices, as well as assessing its own management and performance in order to regularly monitor and assess performance.
The Board of Pathology Technology Australia is elected by the membership from among the Corporate Representatives of Member Companies. Board Members are elected for a 2 year term and appoint a Chair, Deputy-Chair and Treasurer from among their number to serve a 1 year term. More information about the Board of Director’s role and responsibilities can be found in the Pathology Technology Australia Constitution.
| David Basseal Chair, Pathology Technology Australia Chief Commercial officer, Minomic International David Basseal has a diverse professional background that has spanned medical research, business consulting, sales and marketing, and general management. After commnecing his career as a scientific researcher in the field of proteomics, David entered the commerical area wih Accenture before joining life sciencesand diagnoic companies like Bio-Rad Laboratories, Becton Dickinson and Roche, holding leaderhip positions with increasing responsibilities. David has been a Director on the PTA board for 4 years and is the current Chair. |
| Mark Volling Vice Chair, Pathology Technology Australia Regional Managing Director, Abbott I have made myself available for re-election to the Board of Pathology Technology Australia as I believe we as an industry are undergoing a fundamental change in our role within the Australian healthcare system and I wish to continue to actively assist in leading our industry through this change. A change that will drive our IVD industry segment to play a greater role within the broader healthcare environment, to become more interactive with clinicians and patients/consumers directly and to be more broadly recognised for our products, services and the healthcare value we provide the general community. This accelerating move to more personalised health is a direction in healthcare that I am personally very passionate about and is a direction that as an industry we need to embrace wholeheartedly. |
| Mr Vito Trifilo |
| Jenny Carson Head of Marketing, Laboratory DiagnosticsSiemens Healthcare Pty. Ltd
I have been part of the pathology and IVD industry for 35 years and I am passionate about the industry that I have grown up and built a career in. Throughout my career I have witnessed great change and great technological advances. I have been an integral part of the technological move to automation in laboratories and I am excited about the new technologies and assays PTA members continue to bring to our customers and community. We are part of a cutting edge industry and although PTA has already made great strides towards raising our profile there is still much to be done to ensure our community and our government understand the value our industry brings. Although I have no previous board experience, I believe my industry knowledge and my proven capabilities in leadership, strategic planning and communication makes me an ideal candidate to join the PTA board at an ideal time. I believe the COVID 19 pandemic provides a platform for us to showcase our industry, inform the community and advise governments with the kind of visibility we have not enjoyed before, and I think the skills I bring can only enhance PTA’s opportunity to achieve “Action” in 2021. |
| Karen MacLeod Pathology Technology Australia Director and Country Manager, MP Biomedicals Karen’s 30-year career in in the in-vitro diagnostics and pharmaceuticals industries began as a medical scientist in public pathology and includes varied sales and management roles with Australian based global companies such as BioMérieux, Boehringer Mannheim (now Roche) and GSK. Currently Director and Country Manager at MP Biomedicals, she is responsible for all sales, management, and regulatory functions. Karen has a Bachelor of Applied Science and Graduate Diploma in Marketing from UTS, Sydney and has been a member of the IVD Australia Technical and Regulatory Standing Committee since 2011. |
| Tony Feneziani Tony has over 25 years commercial experience in the in vitro diagnostic and life sciences industries. During this time, Tony has undertaken a range of leadership roles including commercial operations, sales and marketing and business development. Tony’s current role at Merck also includes Country Leadership Team membership of the Merck Life Sciences operation in ANZ. |
| Sally Hickman |
| Antoniette Violo |
